CSL and Alentis Announce Global Partnership to Develop and Commercialize Lixudebart for Rare Kidney and Liver Diseases

CSL and Alentis Therapeutics have entered an exclusive global collaboration to co-develop and co-promote lixudebart, a potential first-in-class antibody targeting claudin-1, across kidney, liver and other diseases. The lead indication is ANCA-associated vasculitis with rapidly progressive glomerulonephritis (AAV-RPGN), currently being evaluated in the Phase 2 RENAL trial. The companies will also advance lixudebart in focal segmental glomerulosclerosis (FSGS) and primary sclerosing cholangitis (PSC).

Under the agreement, CSL will make an initial payment of US$355 million to Alentis, which is eligible for up to US$1.2 billion in commercial milestones. CSL will fully fund the Phase 2 RENAL trial, a planned Phase 3 trial in AAV-RPGN, and Phase 2 trials in FSGS and PSC. Once commercialized, global profits will be shared 55% to CSL and 45% to Alentis.

CSL leaders have also shared perspectives on the importance of the alliance, including Hervé Gisserot, EVP, Business Development & Alliance Management, and Stephen Pitt, Ph.D., Vice President and Global Head of Search & Evaluation.

Read the full announcement  |  View the LinkedIn commentary

Previous
Previous

Pathos CEO Iker Huerga Shares How AI Can Move Promising Science Closer to Patients

Next
Next

Travere to Present Nine New Data Presentations at ASN Kidney Week 2026